相关实验视频

Updated: Jun 27, 2025

Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments

Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments

Published on: May 9, 2019

长期的Pegvisomant治疗壮成长:影响骨密度,营业额和微观结构使用HRpQCT

Adriana P Kuker¹, Sanchita Agarwal¹, Elizabeth Shane¹

¹Department of Medicine, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA.

Journal of the Endocrine Society

|May 8, 2024

概括

对于壮症而言,Pegvisomant治疗可能会导致骨密度降低和外围骨微观结构的改变,尽管骨转换标记稳定. 这些骨质缺陷可能会导致治疗患者的脆弱性.

科学领域:

内分泌学在内分泌学.
骨生物学骨生物学骨生物学
代谢性骨疾病代谢性骨疾病

背景情况:

巨症与骨折率的增加和持续的骨微观结构异常有关,即使在治疗后.
维索曼特是一种生长激素受体对抗剂,其对壮症患者骨微观结构的影响以前是未知的.

研究的目的:

研究维索曼治疗对骨矿物质密度,骨循环标志物和骨微型架构的长期影响.

主要方法:

一项纵向研究评估了20名接受维索曼特治疗的壮病患者的面积骨矿物质密度 (BMD) 和骨周转标记 (BTMs).
一项横截面研究评估了17名使用HRpQCT长期接受佩格维索曼特治疗的患者的体积 BMD,微型架构和骨强度,并将其与对照组和其他壮症组进行比较.

主要成果:

长期的佩格维索曼治疗显示,腰椎骨质量得到改善,但男性的部骨质量下降.
与健康对照人群相比,长期服用佩格维索曼特的患者的骨较大,体积骨密度降低,并破坏了轨道骨微架构.
骨循环标志物最初下降,然后在佩格维索曼治疗期间稳定.

结论:

这项研究揭示了与pegvisomant治疗的巨患者的外围骨体积 BMD 和微型架构的缺陷.
稳定的骨转化标志物在长期佩格维索曼治疗中被观察到.
在HRpQCT中发现的骨质缺陷可能会导致治疗壮症的脆弱性.

关键词:

HRpQCT 的使用方法亚克罗梅加利症是什么骨头骨头骨头骨头

更多相关视频

Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects

Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects

Published on: December 10, 2010

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head

Published on: September 27, 2024

相关概念视频

Bone Remodeling

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.

Bone Disorders

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...

Osteoclasts in Bone Remodeling

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...

Hormones and Bone Tissue

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...